West Pharmaceutical Services Inc（WST）今日盘前股价大幅上涨6.07%，引起了市场的广泛关注。
消息面上，该公司发布了强劲的财务预测，预计2026年调整后每股利润将高于华尔街预期，同时其第四季度业绩也超出市场预期。业绩的强劲表现主要得益于其专利产品，包括注射器和注射器针筒的需求旺盛。
具体而言，新型糖尿病和肥胖症治疗药物，如诺和诺德的Ozempic和Wegovy以及礼来的Mounjaro的需求激增，预计将使West Pharma等医疗设备制造商受益，因为该公司为这些药物提供注射笔部件。此外，公司还考虑到了向艾伯维出售SmartDose 3.5 mL体内给药系统的交易，该交易预计将于2026年中期完成，进一步支撑了其收入预测。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.